SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-021934
Filing Date
2021-04-16
Accepted
2021-04-16 17:15:54
Documents
3
Period of Report
2021-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea139554-8k_alkidipharm.htm 8-K 23674
2 EXCLUSIVE PATENT LICENSE AGREEMENT BY AND AMONG SILO PHARMA INC., A DELAWARE COR ea139554ex10-1_alkidipharm.htm EX-10.1 111212
3 AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT, DATED APRIL 12, 2021. ea139554ex10-2_alkidipharm.htm EX-10.2 124955
  Complete submission text file 0001213900-21-021934.txt   261412
Mailing Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020
Business Address ONE ROCKEFELLER PLAZA, 11TH FLOOR NEW YORK NY 10020 347-321-7646
AIkido Pharma Inc. (Filer) CIK: 0000012239 (see all company filings)

IRS No.: 520849320 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-05576 | Film No.: 21832375
SIC: 8731 Services-Commercial Physical & Biological Research